Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15257
UPID:
PTPA_HUMAN
Alternative names:
PP2A, subunit B', PR53 isoform; Phosphotyrosyl phosphatase activator; Serine/threonine-protein phosphatase 2A regulatory subunit 4; Serine/threonine-protein phosphatase 2A regulatory subunit B'
Alternative UPACC:
Q15257; A2A347; A9IZU4; B4DXM4; Q15258; Q53GZ3; Q5TZQ2; Q9BUK1; Q9NNZ7; Q9NNZ8; Q9NNZ9
Background:
The Serine/threonine-protein phosphatase 2A activator, known by alternative names such as PP2A, subunit B', PR53 isoform, and Phosphotyrosyl phosphatase activator, plays a crucial role in protein folding through PPIases acceleration. It modulates the activity and substrate specificity of serine/threonine-protein phosphatase 2A (PP2A) by inducing conformational changes. This protein is also involved in reactivating inactive phosphatase PP2A-phosphatase methylesterase complexes and stimulating phosphotyrosyl phosphatase activity, which is essential for apoptosis regulation.
Therapeutic significance:
Understanding the role of Serine/threonine-protein phosphatase 2A activator could open doors to potential therapeutic strategies.